UY39171A - Composición farmacéutica para administración oral que comprende derivado de aminopirimidina o sal farmacéuticamente aceptable, hidrato, o solvato de esta - Google Patents

Composición farmacéutica para administración oral que comprende derivado de aminopirimidina o sal farmacéuticamente aceptable, hidrato, o solvato de esta

Info

Publication number
UY39171A
UY39171A UY0001039171A UY39171A UY39171A UY 39171 A UY39171 A UY 39171A UY 0001039171 A UY0001039171 A UY 0001039171A UY 39171 A UY39171 A UY 39171A UY 39171 A UY39171 A UY 39171A
Authority
UY
Uruguay
Prior art keywords
solvate
hydrate
pharmaceutically acceptable
acceptable salt
pharmaceutical composition
Prior art date
Application number
UY0001039171A
Other languages
English (en)
Inventor
Jacqueline Maximilien
Gopal Rajan
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of UY39171A publication Critical patent/UY39171A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción proporciona una composición farmacéutica para administración oral que comprende N-(5-(4-(4-((dimetilamino)metil)-3-fenil-1H-pirazol-1-il)pirimidina-2-ilamino)-4-metoxi-2-morfolinofenil)acrilamida o una sal farmacéuticamente aceptable, hidrato, o solvato de esta como un ingrediente activo; y una combinación de (i) un derivado de celulosa y (ii) un azúcar o poliol como diluyentes. Las composiciones descritas se caracterizan por una capacidad de fabricación mejorada, mientras se mantienen los beneficios farmacéuticos de minimizar el efecto de acuerdo con cambios en el entorno de pH en el estómago, poseen excelente estabilidad, y exhiben buena biodisponibilidad.
UY0001039171A 2020-04-14 2021-04-13 Composición farmacéutica para administración oral que comprende derivado de aminopirimidina o sal farmacéuticamente aceptable, hidrato, o solvato de esta UY39171A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063009623P 2020-04-14 2020-04-14
US202063014277P 2020-04-23 2020-04-23

Publications (1)

Publication Number Publication Date
UY39171A true UY39171A (es) 2021-10-29

Family

ID=75562794

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039171A UY39171A (es) 2020-04-14 2021-04-13 Composición farmacéutica para administración oral que comprende derivado de aminopirimidina o sal farmacéuticamente aceptable, hidrato, o solvato de esta

Country Status (13)

Country Link
US (1) US20210322323A1 (es)
EP (1) EP4135669A1 (es)
JP (1) JP2023522634A (es)
KR (1) KR20230002656A (es)
CN (1) CN115484937A (es)
AU (1) AU2021257662A1 (es)
BR (1) BR112022020609A2 (es)
CA (1) CA3180184A1 (es)
IL (1) IL297240A (es)
MX (1) MX2022012898A (es)
TW (1) TW202207940A (es)
UY (1) UY39171A (es)
WO (1) WO2021209893A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200043618A (ko) * 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
CN117425651A (zh) * 2021-06-01 2024-01-19 杭州领业医药科技有限公司 Lazertinib甲磺酸盐的水合物晶型及其制备方法和用途
CN118251220A (zh) * 2022-01-19 2024-06-25 江苏奥赛康药业有限公司 一种包含嘧啶基团的三并环类化合物的组合物及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6437006B1 (en) * 1999-09-27 2002-08-20 American Cyanamid Company Pharmaceutical carrier formulation
EP2076249A2 (en) * 2006-10-27 2009-07-08 FMC Corporation Dry granulation binders, products, and use thereof
EP2198857A1 (en) * 2008-12-19 2010-06-23 Ratiopharm GmbH Oral dispersible tablet
HUE041499T2 (hu) 2012-11-21 2019-05-28 Janssen Biotech Inc Bispecifikus EGFR/C-MET-ellenanyagok
WO2015006752A1 (en) * 2013-07-12 2015-01-15 The Regents Of The University Of California Combination therapies for malaria
GB201402070D0 (en) * 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
PL3207035T3 (pl) 2014-10-13 2020-06-01 Yuhan Corporation Związki i kompozycje do modulowania aktywności zmutowanych kinaz EGFR
JP7539231B2 (ja) * 2016-04-07 2024-08-23 ケモセントリクス，インコーポレーテッド Ｐｄ－１阻害剤又はｐｄ－ｌ１阻害剤と組み合わせてｃｃｒ１アンタゴニストを投与することによる腫瘍負荷の低減
UA126970C2 (uk) * 2017-01-20 2023-03-01 Екселіксіс, Інк. Комбінації кабозантинібу і атезолізумабу для лікування раку
AR111469A1 (es) 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
KR20200043618A (ko) * 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors

Also Published As

Publication number Publication date
CN115484937A (zh) 2022-12-16
KR20230002656A (ko) 2023-01-05
TW202207940A (zh) 2022-03-01
EP4135669A1 (en) 2023-02-22
AU2021257662A1 (en) 2022-12-15
IL297240A (en) 2022-12-01
US20210322323A1 (en) 2021-10-21
JP2023522634A (ja) 2023-05-31
BR112022020609A2 (pt) 2022-11-29
MX2022012898A (es) 2023-01-24
WO2021209893A1 (en) 2021-10-21
CA3180184A1 (en) 2021-10-21
WO2021209893A8 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
UY39171A (es) Composición farmacéutica para administración oral que comprende derivado de aminopirimidina o sal farmacéuticamente aceptable, hidrato, o solvato de esta
CU20110216A7 (es) Derivados aminobutíricos sustituidos como inhibidores de neprilisina
BRPI1011657A2 (pt) derivados aminopropiônicos substituídos como inibidores de neprilisina
BRPI0514735B8 (pt) derivados de pirimidino sulfonamida como moduladores do receptor de quimiocina.
RU2011138962A (ru) Производные 4-изопропилфенилглюцита в качестве ингибиторов sglt1
BRPI0620239B8 (pt) derivados de 2-feniletilamino.
BR112013026257A2 (pt) derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes
BR112020007589A8 (pt) Derivados de benzimidazol e seus usos
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
BR112013026361A2 (pt) derivados de glicosídeo e usos dos mesmos
AR117655A1 (es) Composición farmacéutica para administración oral que comprende derivado de aminopirimidina o su sal
ATE473212T1 (de) Hiv-inhibierende 2-(4-cyanophenyl)-6- hydroxylaminopyrimidine
CY1116664T1 (el) Χρηση ενος ινδαζολο-μεθοξυ-αλκανοϊκου οξεος για την παρασκευη μιας φαρμακευτικης συνθεσης
CL2023000418A1 (es) Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
BR112013031121A2 (pt) composto de acordo com a fórmula i a v, ou um sal farmaceuticamente aceitável, solvato, polimorfo, ou pró-droga do mesmo; composto; polimorfo de sal cloridrato de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h-pirrol-3-il)tiazol-2-il)acetamida (fórmula i); ingrediente ativo constituído do mesmo; composição farmacêutica; polimorfo de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)1h-pirrol-3-il)tiazol-2-il)fenil)acetamida (fórmula i); ingrediente ativo constituído do mesmo; uso de um composto ou sal farmaceuticamente aceitável, solvato, polimorfo ou pró-droga do mesmo e uso de um polimorfo ou ingrediente ativo de sal cloridrato de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h-pirrol-3-il)tiazol-2il)tiazol-2-il)fenil)acetamida (fórmula i) e uso de um polimorfo ou ingrediente ativo de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h1pirrol-3-il)tiazol-2-il)fenil)acetamida(fórmula i) na fabricação de um medicamento
AR121828A1 (es) Composición farmacéutica para administración oral que comprende derivado de aminopirimidina o sal farmacéuticamente aceptable, hidrato o solvato de esta
EA200970570A1 (ru) Макролидные соединения, обладающие противовоспалительной активностью
ECSP055804A (es) Composición farmacéutica
BR112023018766A2 (pt) Moduladores alostéricos negativos de ciclopental[c]pirrol de nr2b
NO20073031L (no) Anvendelse av substistuerte cyklopropansyrederivater for fremstilling av medikamenter for anvendelse i behandlingen av metabolisk syndrom
MX2023010241A (es) Derivados de alfa-d-galatopiranosido triazolil-metil sustituidos.
EA202193266A1 (ru) Антибактериальные производные аминогликозидов
UY30848A1 (es) Uso de derivados de mononitrato de dianhidrohexita?? como agentes reductores de la hipertension ocular
AR064544A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes reductores de la hipertension ocular
UY28534A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos